Integrated Strategies for KRAS Inhibitor Development

As one of the most frequently mutated oncogenes in human cancers, KRAS was long considered an “undruggable” target. Recent landmark approvals of KRAS G12C inhibitors have sparked rapid advancements in KRAS-targeted drug development. However, given the diverse array of KRAS mutational subtypes and the growing challenge of acquired clinical resistance, developing next-generation inhibitors that address broader mutation profiles and effectively overcome resistance remains pivotal for maximizing the clinical value of KRAS-targeted therapies.

Leveraging deep expertise in KRAS biology and translational drug discovery, WuXi Biology and Testing has established a comprehensive end-to-end platform for KRAS-related assays, including highly translational cellular and animal models, as well as rigorous in vivo efficacy evaluations within complex drug-resistant models. Our integrated capabilities are designed to help accelerate the discovery and clinical translation of next-generation KRAS-targeted therapies.

In this white paper, WuXi Biology and Testing explores the evolving challenges and opportunities in KRAS drug discovery, including strategies to support translational research across diverse KRAS mutational subtypes.